Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb;67(2):e28073.
doi: 10.1002/pbc.28073. Epub 2019 Nov 14.

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Eric S Schafer  1   2 , Rachel E Rau  1   2 , Stacey L Berg  1   2 , Xiaowei Liu  3 , Charles G Minard  1 , Alexander J R Bishop  4   5 , J Carolina Romero  4 , M John Hicks  1 , Marvin D Nelson Jr  6 , Stephan Voss  7 , Joel M Reid  8 , Elizabeth Fox  9 , Brenda J Weigel  10 , Susan M Blaney  1   2
Affiliations
Clinical Trial

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Eric S Schafer et al. Pediatr Blood Cancer. 2020 Feb.

Abstract

Purpose: We conducted a phase 1/2 trial of the poly(ADP-ribose) polymerase 1/2 inhibitor talazoparib in combination with low-dose temozolomide (TMZ) to determine the dose-limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetics of this combination in children with recurrent/refractory solid tumors; and to explore clinical activity in Ewing sarcoma (EWS) (NCT02116777).

Methods: Talazoparib (400-600 µg/m2 /dose, maximum daily dose 800-1000 µg) was administered q.d. or b.i.d. orally on day 1 followed by q.d. dosing concomitant with q.d. dosing of oral TMZ (20-55 mg/m2 /day) on days 2 to 6, every 28 days.

Results: Forty patients, aged 4 to 25 years, were enrolled. Talazoparib was increased to 600 µg/m2 /dose b.i.d. on day 1, and q.d. thereafter, with 20 mg/m2 /day of TMZ, without DLTs. TMZ was subsequently increased, during which dose-limiting neutropenia and thrombocytopenia occurred in two of three subjects at 55 mg/m2 /day, two of six subjects at 40 mg/m2 /day, and one of six subjects at 30 mg/m2 /day. During dose-finding, two of five EWS and four of 25 non-EWS subjects experienced prolonged stable disease (SD), and one subject with malignant glioma experienced a partial response. In phase 2, 0 of 10 EWS subjects experienced an objective response; two experienced prolonged SD.

Conclusions: Talazoparib and low-dose TMZ are tolerated in children with recurrent/refractory solid tumors. Reversible neutropenia and thrombocytopenia were dose limiting. The RP2D is talazoparib 600 µg/m2 b.i.d. on day 1 followed by 600 µg/m2 q.d. on days 2 to 6 (daily maximum 1000 µg) in combination with temozolomide 30 mg/m2 /day on days 2 to 6. Antitumor activity was not observed in EWS, and limited antitumor activity was observed in central nervous system tumors.

Keywords: PARP inhibitor; pharmacokinetics; phase 1; talazoparib; temozolomide.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT:

J.M.R. declares immediate family members who have ownership interests (stock) in BioMarin and Novartis. All other authors declare that they have no COI to disclose.

Figures

Figure 1
Figure 1
Computed Tomography (CT) images from a 13 year old female with a malignant disseminated glioma (arrows), Two different levels at Baseline (Baseline A1, B1) compared to the matching levels 3 months later following 2 cycles of treatment (End A2, B2) with talazoparib (600 mg/m2/day) and temozolomide (55 mg/m2/day) demonstrate marked reduction in tumor bulk.
See this image and copyright information in PMC

References

    1. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proceedings of the National Academy of Sciences of the United States of America. Jul 08 1997;94(14):7303–7307. - PMC - PubMed
    1. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer research. Nov 01 2012;72(21):5588–5599. - PMC - PubMed
    1. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nature reviews. Cancer. Apr 2010;10(4):293–301. - PMC - PubMed
    1. Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology. Sep 1 2018;29(9):1939–1947. - PubMed
    1. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England journal of medicine. Aug 23 2018;379(8):753–763. - PMC - PubMed

Publication types

MeSH terms

Associated data